Erectile dysfunction: Anatomical parameters, etiology, diagnosis, and therapy

Archives of Andrology

Volumn 51, Issue 1, 2005, Pages 15-31

  Hafez, E S E ^a   Hafez, S D ^a  

^a Reproductive Health Center   (United States)

Author keywords

Erection; Penis; Pharmacology; Physiology; Sildenafil; Viagra

Indexed keywords

ANTIANDROGEN; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; APOMORPHINE; ATENOLOL; ATROPINE; BENZATROPINE; BICALUTAMIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CLOFIBRATE; CYPROTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUTAMIDE; HYDRALAZINE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PHENTOLAMINE MESYLATE; PHOSPHODIESTERASE V INHIBITOR; PROPANTHELINE BROMIDE; PROSTAGLANDIN E1; SILDENAFIL; SPIRONOLACTONE; TADALAFIL; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VARDENAFIL; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ARTICLE; CORPUS CAVERNOSUM; DOPPLER ECHOGRAPHY; ECHOGRAPHY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; INNERVATION; LYMPHATIC DRAINAGE; ORGANIC IMPOTENCE; PENIS; PENIS ARTERY; PENIS GLANS; PENIS PROSTHESIS; PEYRONIE DISEASE; PREPUCE; PRIAPISM; PRIORITY JOURNAL; REVASCULARIZATION; RISK FACTOR; VACUUM;

HUMANS; IMPOTENCE; MALE; PENIS;

EID: 11144224536     PISSN: 01485016     EISSN: None     Source Type: Journal    
DOI: 10.1080/1485010490475147     Document Type: Article

References (59)

1. Amin Z, Patel U, et al. (1993): Colour Doppler and duplex ultrasound assessment of Peyronie's disease in impotent men. Br J Radiol 66:398-402.
2. Anders EK, Bradley WE, Krane RJ (1983): Nocturnal penile rigidity measured by the snap-gauge band. J. Urol 129:964-966.
3. Andersson KE, Wagner G (1995): Physiology of penile erection. Physiol Rev 75:191-236.
4. Arruda-Olson A, Mahoney DW, et al. (2002): Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. J Am Med Assoc 287:719-725.
5. Batra AK, Lue TF (1991): Penile erection: circulatory physiology. In: Impotence: Diagnosis and Management of Male Erectile Dysfunction. Kirby RS, Carson C, Webster GD (Eds). Oxford: Butterworth-Heinemann, 19-26.
6. Boolel M, Gepi-Attee S, Gingell JC, Allen MJ (1996): Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 78:257-261.
7. Boulton AJM, Selam J-L, Sweeney M, Ziegler D (2001): Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 44:1296-1301.
8. Brock GB, Taylor T, Seger M, and the Vardenafil PROSPECT Group (2002): Efficacy and tolerability of vardenafil in men with erectile dysfunction following radical prostatectomy. Eur Urol Suppl 1:152.
9. Burnett AL (1995): Role of nitric oxide in the physiology of erection. Biol Reprod 52:485-489.
10. Buvat JS, Gingell CJ, et al. (1997): Sildenafil (Viagra), an oral treatment for erectile dysfunction: A 1-year open-label extension study. J Urol 157(Suppl):204.
11. Carson CC, Burnett AL, et al. (2002): The efficacy of sildenafil citrate (Viagra®) in clinical populations. Urology 60:12-27.
12. Dinsmore WW, Alderdice DK (1998): Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatments of patients with erectile dysfunction resistant to other intracavernosal agents. Br J Urol 81:437-440.
13. Furlow WL, Goldwasser B, Gundian JC (1988): Implantation of model AMS700 penile prothesis: Long-term results. J Urol 139:741-742.
14. Godschalk MF, Chen J, et al. (1998): Treatment for erectile failure with prostaglandin E1: a double-blind, placebo-controlled, dose-response study. J Urol 151:1530-1532.
15. Goldstein I, Lue TF, et al. (1998): Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 338:1397-1404.
16. Goldstein I, Young M, et al. (2001): Vardenafil, a new highly selective PDE5 inhibitor, improves erectile function in patients with diabetes mellitus. Diabetes 50 (Suppl 2):114.
17. Guiliano F (2002): Phosphodiesterase type 5 inhibition in erectile dysfunction: an overview. Eur Heart J Suppl. H:H7-12.
18. Heaton JPW (2001): Key issues from the clinical trials of apomorphine SL. World J Urol 19:25-31.
19. Heaton JPW, Morales A, Owen J (1990): Topical glyceryltrinitrate causes measurable penile arterial dilatation in impotent men. J Urol 143:729-731.
20. Heaton JPW, Morales A, et al. (1995): Recovery of erectile function by the oral administration of apomorphine. Urology 45:200-206.
21. Hellstrom WJF, Gittelman M, et al. (2002): Vardenafil for treatment of men with erectile dysfunction. Efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 23:763-771.
22. Kim ED, McVary K (1995): Topical prostaglandin E1 for the treatment of erectile dysfunction. J Urol 153:1828-1830.
23. Kirby RS (1994): Impotence: diagnosis and management of male erectile dysfunction. Br Med J 308:957-961.
24. Kirby RS (2003): An areas of erectile dysfunction, 2nd edition. New York, NY: Parthenon Publish Group.
25. Lerner SE, Melman A, Christ GJ (1993): Review of erectile dysfunction: new insights and more questions. J Urol 149:1246-1255.
26. Levin RM, Wein AJ (1980): Adrenergic alpha receptors out-number beta receptors in human penile corpus cavernosum. Invest Urol 18:225-226.
27. Lue TF (1991): Impotence after radical pelvic surgery: physiology and management. Urol Int 46:259-263.
28. Lee JC, Morales A, Heaton JPW (2000): The prevalence and influence of significant psychiatric abnormalities in men undergoing comprehensive management of organic erectile dysfunction. Intern J Impotence Res 12:47-51.
29. McConnell JD, Bruskewitz R, et al. (1998): The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338:557-563.
30. McCulloch DK, Campbell IW, et al. (1980): The prevalence of diabetic impotence. Diabetologia 18:279-283.
31. McCullough AR, Barada JH, et al. (2002): Achieving treatment optimization with sildenafil citrate (Viagra®) in patients with erectile dysfunction. Urology 60:28-38.
32. McMahon CG, Samali R, Johnson H (2000): Efficacy, safety and patient acceptance of sildenafil as treatment for erectile dysfunction. J Urol 164:1192-1196.
33. Mirone VG, Steif CG (2001): Efficacy of apomorphone SL in erectile dysfunction. BJU Int 88(Suppl 3):25-29.
34. Moreira SG, Brannigan RE, et al. (2000): Side-effect profile of sildenafil citrate (Viagra) in clinical practice. Urology 56:474-476.
35. Naylor AM (1998): Endogenous neurotransmitters mediating penile erection. Br J Urol 81:424-431.
36. Nicolosi A, Moreira ED, et al. (2003): Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology 61:201-206.
37. Padma-Nathan H, Eardley I, et al. (2002): A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 60:67-90.
38. Padma-Nathan H, Hellstrom WJ, et al. and the MUSE Study Group (1997): Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated urethral system for erection (MUSE). N Engl J Med 336:1-7.
39. Padma-Nathan H, McMurray JG, et al. (2001): On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 13:2-9.
40. Padma-Nathan H, Stecher VJ, et al. (2003): Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 62:400-403.
41. Palmer LS, Valcic M, et al. (1994): Characterization of cyclic AMP accumulation in cultured human corpus cavernosum smooth muscle cells. J Urol 152:1308-1314.
42. Patel U, Amin Z, et al. (1993). Colour flow and spectral Doppler imaging after papaverine-induced erection in 220 impotent men: study of temporal patterns and the importance of repeated sampling, velocity asymmetry and vascular anomalies. Clin Radiol 48:18-24.
43. Raina R, Lakin MM, et al. (2003): Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology 62:110-115.
44. Rajfer J, Aronson WJ, et al. (1992): Nitric oxide as a mediator of relaxation of the corpora cavernosa in response to non-adrenergic, non-cholinergic neurotransmission. N Engl J Med 3:90-94.
45. Rendell MS, Rajfer J, et al. (1999): Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. J Am Med Assoc 281:421-426.
46. Rosen R, Riley A, et al. (1997): The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49:822-830.
47. Ruffolo RR, Nichols AJ, et al. (1991): Structure and function of alpha-adrenoceptors. Pharm Rev 43:475-505.
48. Saenz de Tejada I, Knight JR, et al. (2002): Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 25:2159-2164.
49. Saenz de Tejada I, Angulo J, et al. (2001): The phospho-diesterase inhibitory selectivity and the in vivo potency of the new PDE 5 inhibitor vardenafil. Int J Impot Res 13:284-290.
50. Stackl W, Hasun R, Marberger M (1988): Intracavernous injection of prostaglandin E1 in impotent men. J Urol 140:66-68.
51. Steers W, Guay AT, et al. (2001): Assessment of the efficacy and safety of Viagra® (sildenafil citrate) in men with erectile dysfunction during long-term treatment. Int J Impot Res 13:261-267.
52. Stuckey BGA, Jadzinsky MN, et al. (2003): Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes. Results of a randomized controlled trial. Diabetes Care 26:279-284.
53. Virag R, Bouilly P, Frydman D (1985): Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet i:181-184.
54. Virag R, Shoukry K, et al. (1991): Intracavernous self-injection of vasoactive drugs in the treatment of impotence. J Urol 145:287-293.
55. Wagner TH, Patrick DL, et al. (1996): Cross-cultural development of a quality of life measure for men with erection difficulties. Qual Life Res 5:443-449.
56. Wespes E, Schulman CC (1985): Venous leakage: surgical treatment of a curable cause of impotence. J Urol 133:796-798.
57. Wespes E, Schulman C (1993): Venous impotence: pathophysiology, diagnosis and treatment. J Urol 49:1238-1245.
58. Wilson SK, Wahman GE, Lange JL (1988): Eleven years' experience with the inflatable penile prosthesis. J Urol 139:951-952.
59. Witherington R (1989): Vacuum constriction device for management of erectile impotence. J Urol 141:320-322.